Expression of angiogenic factors in chronic myeloid leukaemia: Role of the bcr/abl oncogene, biochemical mechanisms, and potential clinical implications

European Journal of Clinical Investigation, Supplement

Volumn 34, Issue 2, 2004, Pages 2-11

  Sillaber, Christian ^a   Mayerhofer, M ^a   Aichberger, K J ^a   Krauth, M T ^a   Valent, P ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

BCR ABL; CML; Rapamycin; VEGF

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; 4 DEDIMETHYLAMINOSANCYCLINE; ALPHA INTERFERON; ALPHA2B INTERFERON; ANGIOGENIC FACTOR; ANGIOZYME; BCR ABL PROTEIN; CYTOKINE; IMATINIB; IMC 1C11; RAPAMYCIN; RECEPTOR BLOCKING AGENT; THALIDOMIDE; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN ANTIBODY; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; BIOCHEMISTRY; BLAST CELL CRISIS; CELL CLONE; CHRONIC MYELOID LEUKEMIA; CHRONICITY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DISEASE COURSE; DRUG TARGETING; EPIGENETICS; GENE EXPRESSION; GENETIC STABILITY; HUMAN; NONHUMAN; ONCOGENE; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SURVIVAL RATE; CLINICAL FEATURE; LEUKEMIA CELL; SURVIVAL TIME; UPREGULATION;

EID: 4944232027     PISSN: 0960135X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0960-135x.2004.01365.x     Document Type: Review

References (108)

1. Rowley JD. A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 1973;243:290-3.
2. de Klein A, van Kessel AG, Grosveld G, Bartram CR, Hagemeijer A, Bootsma D et al. A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia. Nature 1982;300:765-7.
3. Deininger MW, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukemia. Blood 2000;96:3343-56.
4. Sattler M, Griffin JD. Mechanisms of transformation by the BCR/ABL oncogene. Int J Hematol 2001;73:278-91.
5. Amarante-Mendes GP, McGahon AJ, Nishioka WK, Afar DE, Witte ON, Green DR. Bcl-2-independent Bcr-Abl-mediated resistance to apoptosis: protection is correlated with up regulation of Bcl-xL. Oncogene 1998;16:1383-90.
6. Skorski T, Kanakaraj P, Nieborowska-Skorska M, Ratajczak MZ, Wen SC, Zon G et al. Phosphatidylinositol-3 kinase activity is regulated by BCR/ABL and is required for the growth of Philadelphia chromosome-positive cells. Blood 1995;86:726-36.
7. Pendergast AM, Quilliam LA, Gripe LD, Bassing CH, Dai Z, Li N et al. BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein. Cell 1993;75:175-85.
8. Daley GQ, Van Etten RA, Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 1990;247:824-30.
9. Vardiman JW, Pierre R, Thiele J, Imbert M, Brunning RD, Flandrin G. Chronic myelogenous leukaemia. In: Jaffe, ES, Harris, NL, Stein, H, Vardiman, JW, editors. Tumours of Haematopoietic and Lympoid Tissues. Lyon, France:IARC Press;2001.pp. 20-6.
10. Denburg JA, Wilson WE, Bienenstock J. Basophil production in myeloproliferative disorders: increases during acute blastic transformation of chronic myeloid leukemia. Blood 1982;60:113-20.
11. Denburg JA, Wilson WE, Goodacre R, Bienenstock J. Chronic myeloid leukaemia: evidence for basophil differentiation and histamine synthesis from cultured peripheral blood cells. Br J Haematol 1980;45:13-21.
12. Aguayo A, Kantarjian H, Manshouri T, Gidel C, Estey E, Thomas D et al. Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood 2000;96:2240-5.
13. Lundberg LG, Lerner R, Sundelin P, Rogers R, Folkman J, Palmblad J. Bone marrow in polycythemia vera, chronic myelocytic leukemia, and myelofibrosis has an increased vascularity. Am J Pathol 2000;157:15-9.
14. Krulik M, Smadja N, de Gramont A, Gonzalez-Canali G, Audebert AA, Dray C et al. Sequential karyotype study on Ph-positive chronic myelocytic leukemia. Significance of additional chromosomal abnormalities during disease evolution. Cancer 1987;60:974-9.
15. Mitelman F. The cytogenetic scenario of chronic myeloid leukemia. Leuk Lymphoma 1993;11(Suppl. 1):11-5.
16. Gordon MY, Dowding CR, Riley GP, Goldman JM, Greaves MF. Altered adhesive interactions with marrow stroma of haematopoietic progenitor cells in chronic myeloid leukaemia. Nature 1987;328:342-4.
17. Janowska-Wieczorek A, Majka M, Marquez-Curtis L, Wertheim JA, Turner AR, Ratajczak MZ. Bcr-abl-positive cells secrete angiogenic factors including matrix metalloproteinases and stimulate angiogenesis in vivo in Matrigel implants. Leukemia 2002;16:1160-6.
18. Mayerhofer M, Valent P, Sperr WR, Griffin JD, Sillaber C. BCR/ABL induces expression of vascular endothelial growth factor and its transcriptional activator, hypoxia inducible factor, through a pathway involving phosphoinositide 3-kinase and the mammalian target of rapamycin. Blood 2002;100:3767-75.
19. Krejci P, Dvorakova D, Krahulcova E, Pachernik J, Mayer J, Hampl A et al. FGF-2 abnormalities in B cell chronic lymphocytic and chronic myeloid leukemias. Leukemia 2001;15:228-37.
20. Hino M, Inaba M, Goto H, Nishizawa Y, Tatsumi N, Nishino T et al. Hepatocyte growth factor levels in bone marrow plasma of patients with leukaemia and its gene expression in leukaemic blast cells. Br J Cancer 1996;73:119-23.
21. Muller A, Lange K, Gaiser T, Hofmann M, Bartels H, Feller AC et al. Expression of angiopoietin-1 and its receptor TEK in hematopoietic cells from patients with myeloid leukemia. Leuk Res 2002;26:163-8.
22. Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev 1997;18:4-25.
23. Forsythe JA, Jiang BH, Iyer NV, Agani F, Leung SW, Koos RD et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 1996;16:4604-13.
24. Shweiki D, Itin A, Soffer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992;359:843-5.
25. Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 1999;13:9-22.
26. Gerber HP, Malik AK, Solar GP, Sherman D, Liang XH, Meng G et al. VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism. Nature 2002;417:954-8.
27. Wimazal F, Jordan JH, Sperr WR, Chott A, Dabbass S, Lechner K et al. Increased angiogenesis in the bone marrow of patients with systemic mastocytosis. Am J Pathol 2002;160:1639-45.
28. Verstovsek S, Kantarjian H, Manshouri T, Cortes J, Giles FJ, Rogers A et al. Prognostic significance of cellular vascular endothelial growth factor expression in chronic phase chronic myeloid leukemia. Blood 2002;99:2265-7.
29. Ratajczak MZ, Ratajczak J, Machalinski B, Majka M, Marlicz W, Carter A et al. Role of vascular endothelial growth factor (VEGF) and placenta-derived growth factor (PlGF) in regulating human haemopoietic cell growth. Br J Haematol 1998;103:969-79.
30. Basilico C, Moscatelli D. The FGF family of growth factors and oncogenes. Adv Cancer Res 1992;59:115-65.
31. Gospodarowicz D, Ferrara N, Schweigerer L, Neufeld G. Structural characterization and biological functions of fibroblast growth factor. Endocr Rev 1987;8:95-114.
32. Lobb RR, Alderman EM, Fett JW. Induction of angiogenesis by bovine brain derived class 1 heparin-binding growth factor. Biochemistry 1985;24:4969-73.
33. Gibran NS, Isik FF, Heimbach DM, Gordon D. Basic fibroblast growth factor in the early human burn wound. J Surg Res 1994;56:226-34.
34. LeGrand EK, Burke JF, Costa DE, Kiorpes TC. Dose responsive effects of PDGF-BB, PDGF-AA, EGF, and bFGF on granulation tissue in a guinea pig partial thickness skin excision model. Growth Factors 1993;8:307-14.
35. Gabrilove JL, White K, Rahman Z, Wilson EL. Stem cell factor and basic fibroblast growth factor are synergistic in augmenting committed myeloid progenitor cell growth. Blood 1994;83:907-10.
36. Allouche M, Bikfalvi A. The role of fibroblast growth factor-2 (FGF-2) in hematopoiesis. Prog Growth Factor Res 1995;6:35-48.
37. Gabbianelli M, Sargiacomo M, Pelosi E, Testa U, Isacchi G, Peschle C. Pure human hematopoietic progenitors: permissive action of basic fibroblast growth factor. Science 1990;249:1561-4.
38. Klagsbrun M, Sasse J, Sullivan R, Smith JA. Human tumor cells synthesize an endothelial cell growth factor that is structurally related to basic fibroblast growth factor. Proc Natl Acad Sci USA 1986;83:2448-52.
39. Moscatelli D, Presta M, Joseph-Silverstein J, Rifkin DB. Both normal and tumor cells produce basic fibroblast growth factor. J Cell Physiol 1986;129:273-6.
40. Singh RK, Gutman M, Bucana CD, Sanchez R, Llansa N, Fidler IJ. Interferons alpha and beta down-regulate the expression of basic fibroblast growth factor in human carcinomas. Proc Natl Acad Sci USA 1995;92:4562-6.
41. Vlodavsky I, Fuks Z, Ishai-Michaeli R, Bashkin P, Levi E, Korner G et al. Extracellular matrix-resident basic fibroblast growth factor: implication for the control of angiogenesis. J Cell Biochem 1991;45:167-76.
42. Bikfalvi A, Klein S, Pintucci G, Rifkin DB. Biological roles of fibroblast growth factor-2. Endocr Rev 1997;18:26-45.
43. Ratajczak MZ, Ratajczak J, Skorska M, Marlicz W, Calabretta B, Pletcher CH Jr et al. Effect of basic (FGF-2) and acidic (FGF-1) fibroblast growth factors on early haemopoietic cell development. Br J Haematol 1996;93:772-82.
44. Komatsu K, Nakamura H, Masaoka T, Akedo H. Synergistic effects of basic fibroblast growth factor and hematopoietic growth factors on colony formation of K562 human leukemic cells. Leukemia 1995;9:1565-8.
45. Musolino C, Calabro' L, Bellomo G, Martello F, Loteta B, Pezzano C et al. Soluble angiogenic factors: implications for chronic myeloproliferative disorders. Am J Hematol 2002;69:159-63.
46. Rosen EM, Goldberg ID. Scatter factor and angiogenesis. Adv Cancer Res 1995;67:257-79.
47. Tamura M, Arakaki N, Tsubouchi H, Takada H, Daikuhara Y. Enhancement of human hepatocyte growth factor production by interleukin-1α and -1β and tumor necrosis factor-β by fibroblasts in culture. J Biol Chem 1993;268:8140-5.
48. Grant DS, Kleinman HK, Goldberg ID, Bhargava MM, Nickoloff BJ, Kinsella JL et al. Scatter factor induces blood vessel formation in vivo. Proc Natl Acad Sci USA 1993;90:1937-41.
49. Naidu YM, Rosen EM, Zitnick R, Goldberg I, Park M, Naujokas M et al. Role of scatter factor in the pathogenesis of AIDS-related Kaposi sarcoma. Proc Natl Acad Sci USA 1994;91:5281-5.
50. Bottaro DP, Rubin JS, Faletto DL, Chan AM, Kmiecik TE, VandeWoude GF et al. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science 1991;251:802-4.
51. Yamashita J, Ogawa M, Yamashita S, Nomura K, Kuramoto M, Saishoji T et al. Immunoreactive hepatocyte growth factor is a strong and independent predictor of recurrence and survival in human breast cancer. Cancer Res 1994;54:1630-3.
52. Joseph A, Weiss GH, Jin L, Fuchs A, Chowdhury S, O'Shaugnessy P et al. Expression of scatter factor in human bladder carcinoma. J Natl Cancer Inst 1995;87:372-7.
53. Ratajczak MZ, Marlicz W, Ratajczak J, Wasik M, Machalinski B, Carter A et al. Effect of hepatocyte growth factor on early human haemopoietic cell development. Br J Haematol 1997;99:228-36.
54. Dirks RP, Bloemers HP. Signals controlling the expression of PDGF. Mol Biol Rep 1995;22:1-24.
55. Heldin CH. Structural and functional studies on platelet-derived growth factor. EMBO J 1992;11:4251-9.
56. Michalevicz R, Katz F, Stroobant P, Janossy G, Tindle RW, Hoffbrand AV. Platelet-derived growth factor stimulates growth of highly enriched multipotent haemopoietic progenitors. Br J Haematol 1986;63:591-8.
57. Delwiche F, Raines E, Powell J, Ross R, Adamson J. Platelet-derived growth factor enhances in vitro erythropoiesis via stimulation of mesenchymal cells. J Clin Invest 1985;76:137-42.
58. Katz FE, Michalevicz R, Lam G, Hoffbrand AV, Goldman JM. Effect of platelet-derived growth factor on enriched populations of haemopoietic progenitors from patients with chronic myeloid leukaemia. Leuk Res 1987;11:339-44.
59. Heldin CH, Backstrom G, Ostman A, Hammacher A, Ronnstrand L, Rubin K et al. Binding of different dimeric forms of PDGF to human fibroblasts: evidence for two separate receptor types. EMBO J 1988;7:1387-93.
60. Hart CE, Forstrom JW, Kelly JD, Seifert RA, Smith RA, Ross R et al. Two classes of PDGF receptor recognize different isoforms of PDGF. Science 1988;240:1529-31.
61. Ross R. Platelet-derived growth factor. Lancet 1989;1:1179-82.
62. Gersuk GM, Carmel R, Pattengale PK. Platelet-derived growth factor concentrations in platelet-poor plasma and urine from patients with myeloproliferative disorders. Blood 1989;74:2330-4.
63. Kimura A, Nakata Y, Hyodo H, Kuramoto A, Satow Y. Platelet-derived growth factor expression in accelerated and blastic phase of chronic myelogenous leukaemia with myelofibrosis. Br J Haematol 1994;86:303-7.
64. Kimura A, Katoh O, Hyodo H, Kuramoto A, Satow Y. Platelet derived growth factor expression, myelofibrosis and chronic myelogenous leukemia. Leuk Lymphoma 1995;18:237-42.
65. Davis S, Aldrich TH, Jones PF, Acheson A, Compton DL, Jain V et al. Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning. Cell 1996;87:1161-9.
66. Jones N, Iljin K, Dumont DJ, Alitalo K. Tie receptors: new modulators of angiogenic and lymphangiogenic responses. Nat Rev Mol Cell Biol 2001;2:257-67.
67. Loughna S, Sato TN. Angiopoietin and Tie signaling pathways in vascular development. Matrix Biol 2001;20:319-25.
68. Dumont DJ, Yamaguchi TP, Conlon RA, Rossant J, Breitman ML. tek, a novel tyrosine kinase gene located on mouse chromosome 4, is expressed in endothelial cells and their presumptive precursors. Oncogene 1992;7:1471-80.
69. Kontos CD, Stauffer TP, Yang WP, York JD, Huang L, Blanar MA et al. Tyrosine 1101 of Tie2 is the major site of association of p85 and is required for activation of phosphatidylinositol 3-kinase and Akt. Mol Cell Biol 1998;18:4131-40.
70. Jones N, Master Z, Jones J, Bouchard D, Gunji Y, Sasaki H et al. Identification of Tek/Tie2 binding partners. Binding to a multifunctional docking site mediates cell survival and migration. J Biol Chem 1999;274:30896-905.
71. Korpelainen EI, Karkkainen M, Gunji Y, Vikkula M, Alitalo K. Endothelial receptor tyrosine kinases activate the STAT signaling pathway: mutant Tie-2 causing venous malformations signals a distinct STAT activation response. Oncogene 1999;18:1-8.
72. Suri C, Jones PF, Patan S, Bartunkova S, Maisonpierre PC, Davis S et al. Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell 1996;87:1171-80.
73. Sato TN, Tozawa Y, Deutsch U, Wolburg-Buchholz K, Fujiwara Y, Gendron-Maguire M et al. Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation. Nature 1995;376:70-4.
74. Dumont DJ, Gradwohl G, Fong GH, Puri MC, Gertsenstein M, Auerbach A et al. Dominant-negative and targeted null mutations in the endothelial receptor tyrosine kinase, tek, reveal a critical role in vasculogenesis of the embryo. Genes Dev 1994;8:1897-909.
75. Hattori K, Dias S, Heissig B, Hackett NR, Lyden D, Tateno M et al. Vascular endothelial growth factor and angiopoietin-1 stimulate postnatal hematopoiesis by recruitment of vasculogenic and hematopoietic stem cells. J Exp Med 2001;193:1005-14.
76. Hashiyama M, Iwama A, Ohshiro K, Kurozumi K, Yasunaga K, Shimizu Y et al. Predominant expression of a receptor tyrosine kinase, TIE, in hematopoietic stem cells and B cells. Blood 1996;87:93-101.
77. Hsu HC, Ema H, Osawa M, Nakamura Y, Suda T, Nakauchi H. Hematopoietic stem cells express Tie-2 receptor in the murine fetal liver. Blood 2000;96:3757-62.
78. Huang XL, Takakura N, Suda T. In vitro effects of angiopoietins and VEGF on hematopoietic and endothelial cells. Biochem Biophys Res Commun 1999;264:133-8.
79. Lin P, Polverini P, Dewhirst M, Shan S, Rao PS, Peters K. Inhibition of tumor angiogenesis using a soluble receptor establishes a role for Tie2 in pathologic vascular growth. J Clin Invest 1997;100:2072-8.
80. Stratmann A, Risau W, Plate KH. Cell type-specific expression of angiopoietin-1 and angiopoietin-2 suggests a role in glioblastoma angiogenesis. Am J Pathol 1998;153:1459-66.
81. Samorapoompichit P, Kiener HP, Schernthaner GH, Jordan JH, Agis H, Wimazal F et al. Detection of tryptase in cytoplasmic granules of basophils in patients with chronic myeloid leukemia and other myeloid neoplasms. Blood 2001;98:2580-3.
82. Blair RJ, Meng H, Marchese MJ, Ren S, Schwartz LB, Tonnesen MG et al. Human mast cells stimulate vascular tube formation. Tryptase is a novel, potent angiogenic factor. J Clin Invest 1997;99:2691-700.
83. Federico MH, Snitcovsky I, Maistro S, Katayama ML, Figueiredo VL, Brentani MM. Integrin receptors and TGF-beta expression in chronic myeloid leukemia cells. Braz J Med Biol Res 1994;27:2267-71.
84. Daley GQ, Baltimore D. Transformation of an interleukin 3-dependent hematopoietic cell line by the chronic myelogenous leukemia-specific P210bcr/abl protein. Proc Natl Acad Sci USA 1988;85:9312-6.
85. Verfaillie CM, Hurley R, Lundell BI, Zhao C, Bhatia R. Integrin-mediated regulation of hematopoiesis: do BCR/ABL-induced defects in integrin function underlie the abnormal circulation and proliferation of CML progenitors? Acta Haematol 1997;97:40-52.
86. Konopka JB, Watanabe SM, Witte ON. An alteration of the human c-abl protein in K562 leukemia cells unmasks associated tyrosine kinase activity. Cell 1984;37:1035-42.
87. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996;2:561-6.
88. Horita M, Andreu EJ, Benito A, Arbona C, Sanz C, Benet I et al. Blockade of the Bcr-Abl kinase activity induces apoptosis of chronic myelogenous leukemia cells by suppressing signal transducer and activator of transcription 5-dependent expression of Bcl-xL. J Exp Med 2000;191:977-84.
89. Sillaber C, Gesbert F, Frank DA, Sattler M, Griffin JD. STAT5 activation contributes to growth and viability in Bcr/Abl-transformed cells. Blood 2000;95:2118-25.
90. Blancher C, Moore JW, Robertson N, Harris AL. Effects of ras and von Hippel-Lindau (VHL) gene mutations on hypoxia-inducible factor (HIF)-1α, HIF-2α, and vascular endothelial growth factor expression and their regulation by the phosphatidylinositol 3′-kinase/Akt signaling pathway. Cancer Res 2001;61:7349-55.
91. Fiedler W, Graeven U, Ergun S, Verago S, Kilic N, Stockschlader M et al. Vascular endothelial growth factor, a possible paracrine growth factor in human acute myeloid leukemia. Blood 1997;89:1870-5.
92. Bellamy WT, Richter L, Sirjani D, Roxas C, Glinsmann-Gibson B, Frutiger Y et al Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes. Blood 2001;97:1427-34.
93. Sun L, McMahon G. Inhibition of tumor angiogenesis by synthetic receptor tyrosine kinase inhibitors. Drug Discov Today 2000;5:344-53.
94. Abraham RT, Wiederrecht GJ. Immunopharmacology of rapamycin. Annu Rev Immunol 1996;14:483-510.
95. Guba M, von Breitenbuch P, Steinbauer M, Koehl G, Flegel S, Hornung M et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 2002;8:128-35.
96. Muthukkumar S, Ramesh TM, Bondada S. Rapamycin, a potent immunosuppressive drug, causes programmed cell death in B lymphoma cells. Transplantation 1995;60:264-70.
97. Seufferlein T, Rozengurt E. Rapamycin inhibits constitutive p70s6k phosphorylation, cell proliferation, and colony formation in small cell lung cancer cells. Cancer Res 1996;56:3895-7.
98. Hosoi H, Dilling MB, Shikata T, Liu LN, Shu L, Ashmun RA et al. Rapamycin causes poorly reversible inhibition of mTOR and induces p53-independent apoptosis in human rhabdomyosarcoma cells. Cancer Res 1999;59:886-94.
99. Talpaz M, McCredie KB, Mavligit GM, Gutterman JU. Leukocyte interferon-induced myeloid cytoreduction in chronic myelogenous leukemia. Blood 1983;62:689-92.
100. Talpaz M, Kantarjian HM, McCredie K, Trujillo JM, Keating MJ, Gutterman JU. Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha A in chronic myelogenous leukemia. N Engl J Med 1986;314:1065-9.
101. Bhatia R, Wayner EA, McGlave PB, Verfaillie CM. Interferon-α restores normal adhesion of chronic myelogenous leukemia hematopoietic progenitors to bone marrow stroma by correcting impaired β1 integrin receptor function. J Clin Invest 1994;94:384-91.
102. Bhatia R, McCarthy JB, Verfaillie CM. Interferon-α restores normal β1 integrin-mediated inhibition of hematopoietic progenitor proliferation by the marrow microenvironment in chronic myelogenous leukemia. Blood 1996;87:3883-91.
103. Dowding C, Guo AP, Osterholz J, Siczkowski M, Goldman J, Gordon M. Interferon-α overrides the deficient adhesion of chronic myeloid leukemia primitive progenitor cells to bone marrow stromal cells. Blood 1991;78:499-505.
104. Upadhyaya G, Cuba SC, Sih SA, Feinberg AP, Talpaz M, Kantarjian HM et al. Interferon-α restores the deficient expression of the cytoadhesion molecule lymphocyte function antigen-3 by chronic myelogenous leukemia progenitor cells. J Clin Invest 1991;88:2131-6.
105. Selleri C, Sato T, Del Vecchio L, Luciano L, Barren AJ, Rotoli B et al Involvement of Fas-mediated apoptosis in the inhibitory effects of interferon-α in chronic myelogenous leukemia. Blood 1997;89:957-64.
106. Sawyers CL, Hochhaus A, Feldman E, Goldman JM, Miller CB, Ottmann OG et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 2002;99:3530-9.
107. Kantarjian HM, Talpaz M, O'Brien S, Smith TL, Giles FJ, Faderl S et al. Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-α: follow-up results. Clin Cancer Res 2002;8:2177-87.
108. Beham-Schmid C, Apfelbeck U, Sill H, Tsybrovsky O, Hofler G, Haas OA et al. Treatment of chronic myelogenous leukemia with the tyrosine kinase inhibitor STI571 results in marked regression of bone marrow fibrosis. Blood 2002:99:381-3.